SCHEMBL21611961

SCHEMBL21611961

Clc1cc(SCc2nc3cc(Oc4ccccc4)ccc3[nH]2)ccn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 8/20 0.46
▸ SMN1; SMN2 Q16637 8/20 0.46
▸ NPC1 O15118 7/20 0.46
▸ CYP1A2 P05177 2/20 0.46
▸ CYP3A4 P08684 2/20 0.46
▸ CYP2D6 P10635 2/20 0.46
▸ CYP2C9 P11712 2/20 0.46
▸ CYP2C19 P33261 2/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ POLB P06746 2/20 0.46
▸ GRIN1 Q05586 5/20 0.43
▸ GRIN2B Q13224 5/20 0.43
▸ LMNA P02545 4/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ MAPT P10636 2/20 0.41
▸ HPGD P15428 2/20 0.40
▸ HTT P42858 1/20 0.40
▸ MAPK1 P28482 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24027398 0.87 SMN1; SMN2 (0.46) RAB9ASMN1; SMN2NPC1CYP1A2CYP3A4
SCHEMBL24027326 0.85 RAB9A (0.44) RAB9ASMN1; SMN2NPC1CYP1A2CYP3A4
SCHEMBL21611983 0.85 PDE10A (0.48) RAB9ASMN1; SMN2NPC1CYP1A2CYP3A4
SCHEMBL21612005 0.82 RAB9A (0.43) RAB9ASMN1; SMN2NPC1CYP1A2CYP3A4
SCHEMBL7807068 0.78 GRIN1 (0.56) RAB9ASMN1; SMN2NPC1MEN1KMT2A
Hydrochloric Acid SCHEMBL8474413 0.76 GRIN1 (0.55) RAB9ASMN1; SMN2NPC1MEN1KMT2A
SCHEMBL21612004 0.76 PDE10A (0.44) RAB9ASMN1; SMN2NPC1CYP1A2CYP3A4
SCHEMBL24027392 0.76 NPC1 (0.43) RAB9ASMN1; SMN2NPC1CYP1A2CYP3A4
SCHEMBL21611967 0.76 PDE10A (0.42) RAB9ASMN1; SMN2NPC1CYP1A2CYP3A4
SCHEMBL21612025 0.76 LMNA (0.41) RAB9ASMN1; SMN2NPC1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210353606-A1 PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2021-11-18 — — US disclosed
EP-3818045-A1 PQSR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2021-05-12 — — EP disclosed
WO-2020007938-A1 PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2020-01-09 — — WO disclosed
WO-2020007938-A1 PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2020-01-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210353606-A1 PqsR INVERSE AGONISTS QRFPR, P2RY11, QARS1 RAB9A 722/4885SMN1; SMN2 4555/4885NPC1 4357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback